• 1.華中科技大學同濟醫(yī)學院附屬協(xié)和醫(yī)院普通外科(武漢 430022);;
  • 2.華中科技大學同濟醫(yī)學院附屬協(xié)和醫(yī)院普通外科研究室;;
  • 通訊作者： 陶凱雄;

目的檢測黑色素瘤抗原基因-3(MAGE-3)在直腸癌中的表達,探索其與直腸癌臨床病理的關系及其在直腸癌免疫治療中的應用價值。
方法采用RT-PCR法，對33例直腸癌患者的癌組織及其相應距腫瘤邊緣（5±1） cm的癌旁組織和手術切緣（乙狀結腸端）以及3例直腸息肉標本（無瘤）的MAGE-3的表達情況進行檢測，并對RT-PCR擴增產物中的目的基因片段進行DNA測序驗證。
結果33例直腸癌組織中，MAGE-3基因的表達陽性率為42.42%(14/33)，在癌旁組織和手術切緣組織中，MAGE-3基因的表達陽性率分別為18.18%(6/33)和15.15%(5/33)，3例直腸息肉標本未見MAGE-3表達。腫瘤組織MAGE-3基因表達陽性率均顯著高于癌旁組織和手術切緣組織(P＜0.05)； 而與患者年齡、性別、腫瘤組織學類型、Dukes分期及淋巴結轉移無關(P gt;0.05)。
結論基于MAGE-3基因在直腸癌中的高表達率，MAGE-3表達的蛋白可以作為一種有前途的靶點用于免疫治療，同時有望成為一種篩查和隨訪指標。

引用本文： 李新明,陶凱雄,王國斌,張寧,吳相柏,張景輝,田源. 黑色素瘤抗原基因-3在直腸癌的表達及意義. 中國普外基礎與臨床雜志, 2006, 13(3): 308-310下轉320. doi: 復制

版權信息： ?四川大學華西醫(yī)院華西期刊社《中國普外基礎與臨床雜志》版權所有，未經(jīng)授權不得轉載、改編

1. [Ｊ]. Int J Cancer, 2003; 104(4)∶ 482.
2. [Ｊ]. Clin Cancer Res, 2003； 9(7)∶2447.
3.
4. [Ｊ]. Nihon Rinsho Meneki Gakkai Kaishi, 1997； 20(2)∶95.
5. [Ｊ]. J Korean Med Sci， 2002; 17(4)∶497.
6. [Ｊ]. Arch Pathol Lab Med, 1998； 122(6)∶551.
7.
8. [Ｊ]. Ann Surg, 1996； 224(2)∶183.
9. [Ｊ]. Cancer Lett， 2004; 208(2)∶197.
10. Eichmuller S, Usener D, Thiel D, et al. Tumorspecific antigens in cutaneous Tcell lymphoma: expression and seroreactivity.
11. Ullenhag GJ, Frodin JE, Mosolits S, et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen EpCAM/KSA (ALVACKSA) and granulocyte macrophage colonystimulating factor induced a tumorspecific cellular immune response.
12. Nishimura S, Fujita M, Terata N, et al. Expression of MAGE genes in colorectal carcinomas.
13. Park MS, Park JW, Jeon CH, et al. Expression of melanoma antigenencoding genes (MAGE) by common primers for MAGEA1 toA6 in colorectal carcinomas among Koreans.
14. Hasegawa H, Mori M, Haraguchi M, et al. Expression spectrum of melanoma antigenencoding gene family members in colorectal carcinoma.
15. Mori M, Inoue H, Mimori K, et al. Expression of MAGE genes in human colorectal carcinoma.
16. Gerhardt A, Usener D, Keese M, et al. Tissue expression and seroreactivity of tumorspecific antigens in colorectal cancer.
  1. 1. [Ｊ]. Int J Cancer, 2003; 104(4)∶ 482.
  2. 2. [Ｊ]. Clin Cancer Res, 2003； 9(7)∶2447.
  3. 3.
  4. 4. [Ｊ]. Nihon Rinsho Meneki Gakkai Kaishi, 1997； 20(2)∶95.
  5. 5. [Ｊ]. J Korean Med Sci， 2002; 17(4)∶497.
  6. 6. [Ｊ]. Arch Pathol Lab Med, 1998； 122(6)∶551.
  7. 7.
  8. 8. [Ｊ]. Ann Surg, 1996； 224(2)∶183.
  9. 9. [Ｊ]. Cancer Lett， 2004; 208(2)∶197.
  10. 10. Eichmuller S, Usener D, Thiel D, et al. Tumorspecific antigens in cutaneous Tcell lymphoma: expression and seroreactivity.
  11. 11. Ullenhag GJ, Frodin JE, Mosolits S, et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen EpCAM/KSA (ALVACKSA) and granulocyte macrophage colonystimulating factor induced a tumorspecific cellular immune response.
  12. 12. Nishimura S, Fujita M, Terata N, et al. Expression of MAGE genes in colorectal carcinomas.
  13. 13. Park MS, Park JW, Jeon CH, et al. Expression of melanoma antigenencoding genes (MAGE) by common primers for MAGEA1 toA6 in colorectal carcinomas among Koreans.
  14. 14. Hasegawa H, Mori M, Haraguchi M, et al. Expression spectrum of melanoma antigenencoding gene family members in colorectal carcinoma.
  15. 15. Mori M, Inoue H, Mimori K, et al. Expression of MAGE genes in human colorectal carcinoma.
  16. 16. Gerhardt A, Usener D, Keese M, et al. Tissue expression and seroreactivity of tumorspecific antigens in colorectal cancer.